Research Grade Alefacept

Description: Alefacept (BS11215) is a research-grade recombinant antibody targeting CD2. Produced in mammalian cells with native-like glycosylation.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species:
Isotype: Fusion-[CD58(LFA3,lymphocytefunctionassociatedantigen3)]2-IGHG1Fc(Fragmentconstant)
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 1mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality:
Applications: Research Grade Biosimilar
Target: Erythrocytereceptor,SRBC,T-cellsurfaceantigenCD2,Rosettereceptor,CD2,LFA-3receptor,T-cellsurfaceantigenT11/Leu-5,LFA-2
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: CD58-Fc,LFA3-Fc,CAS:222535-22-0
Background: T-cell surface antigen CD2 (LFA-2/OX-34) is a ~39 kDa protein. CD2 interacts with lymphocyte function-associated antigen CD58 (LFA-3) and CD48/BCM1 to mediate adhesion between T-cells and other cell types. CD2 is implicated in the triggering of T-cells, the cytoplasmic domain is implicated in the signaling function.
Note: For research use only. Not suitable for clinical or therapeutic use.